1105. Vibriocidal titer variation and likelihood of protection in children compared to adults in a cholera endemic area
Session: Poster Abstract Session: Enteric Infections
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • 9-4 Alaina Ritter IDWeek Poster.pdf (942.3 kB)
  • Background: Vibrio cholerae, the causative agent of cholera, is responsible for significant morbidity and mortality worldwide. Children less than 5 years old have the highest disease burden of cholera in endemic areas. While children develop serum vibriocidal antibody responses to cholera vaccines, they derive less protection from vaccination compared to adults. The aim of our study is to determine if the vibriocidal immune responses to V. cholerae infection are equally accurate as markers of protection in all age groups.

    Methods: Cholera patients and their household contacts, who are known to be at high risk of V. cholerae infection, were enrolled between 2001 – 2017 in Dhaka, Bangladesh. Baseline vibriocidal titers were measured at the time of enrollment of household contacts, and participants were followed prospectively for development of V. cholerae infection.

    Results: We studied 50 contacts < 5 years old (“young children”), 228 contacts 5-16 years old (“older children”), and 548 contacts > 16 years old (“adults”). The baseline serum vibriocidal titer was higher in contacts who remained uninfected from all age groups than in contacts who developed cholera during the follow-up period (young children: P = 0.0092; older children: P = 0.0003, adults: P = 0.0012).

    Conclusion: We found that higher vibriocidal antibody titers were associated with protection against V. cholerae infection across all three age categories. These findings may help increase our understanding of the protective immune response against V. cholerae infection and have importance for future vaccine development strategies.

    Acknowledgments:This research was supported by Massachusetts General Hospital training grant T32AI007061.

    Alaina Ritter, MD1, Fahima Chowdhury, MBBS2, Rachel Becker, BS1, Taufiq Bhuiyan, PhD2, Ashraful Khan, MBBS2, Edward T. Ryan, MD, DTMH, FIDSA1, Stephen B. Calderwood, MD, FIDSA3, Regina LaRocque, MD/MPH1, Jason Harris, MD, MPH, FIDSA3, Firdausi Qadri, PhD2 and Ana Weil, MD, MPH1, (1)Infectious Diseases Division, Massachusetts General Hospital, Boston, MA, (2)Infectious Diseases Division, International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh, (3)Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA

    Disclosures:

    A. Ritter, None

    F. Chowdhury, None

    R. Becker, None

    T. Bhuiyan, None

    A. Khan, None

    E. T. Ryan, None

    S. B. Calderwood, None

    R. LaRocque, None

    J. Harris, None

    F. Qadri, None

    A. Weil, None

    See more of: Enteric Infections
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.